regenerating family member 1 betaGenealiases: PSPS2 · REGH · REGI-BETA · REGL
Q-omics provides the consensus-scored REG1B profile across patient tissues and cancer cell-line models. REG1B expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, REG1B is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, REG1B RNA expression shows 7,280 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight ACC, COAD, and PDAC as cancer lineages where REG1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for REG1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes REG1B survival associations across molecular data types. REG1B RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible REG1B RNA expression–survival associations across cancer types. High REG1B expression shows unfavorable associations in ACC, UVM, SKCM, LUAD, CESC and SCLC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify ACC as the clearest survival context for REG1B RNA expression.
This table summarizes REG1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for REG1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. REG1B shows lower tumor expression in STAD and higher tumor expression in COAD, KIRC, LIHC, READ and CHOL. The COAD box plot shows higher REG1B RNA expression in tumor versus normal tissue (log2 FC = +3.705, t-test p < 0.001).
This table shows molecular features associated with REG1B in patient tissues and cancer cell lines. In patient samples, REG1B shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, REG1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
